First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and ...
Introduction Pain affects an estimated one in five individuals worldwide and represents a major global health challenge.1 While acute pain serves as a protective mechanism, persistent or severe pain can profoundly diminish quality of life and lead to …